Literature DB >> 17203364

Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study.

Ravindra G Kulkarni1, Palukuri Srivani, Garlapati Achaiah, G Narahari Sastry.   

Abstract

The p38 protein kinase is a serine-threonine mitogen activated protein kinase, which plays an important role in inflammation and arthritis. A combined study of 3D-QSAR and molecular docking has been undertaken to explore the structural insights of pyrazolyl urea p38 kinase inhibitors. The 3D-QSAR studies involved comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA). The best CoMFA model was derived from the atom fit alignment with a cross-validated r (2 )(q (2)) value of 0.516 and conventional r (2) of 0.950, while the best CoMSIA model yielded a q (2) of 0.455 and r (2) of 0.979 (39 molecules in training set, 9 molecules in test set). The CoMFA and CoMSIA contour maps generated from these models provided inklings about the influence of interactive molecular fields in the space on the activity. GOLD, Sybyl (FlexX) and AutoDock docking protocols were exercised to explore the protein-inhibitor interactions. The integration of 3D-QSAR and molecular docking has proffered essential structural features of pyrazolyl urea inhibitors and also strategies to design new potent analogues with enhanced activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17203364     DOI: 10.1007/s10822-006-9092-9

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  32 in total

Review 1.  The p38 signal transduction pathway: activation and function.

Authors:  K Ono; J Han
Journal:  Cell Signal       Date:  2000-01       Impact factor: 4.315

Review 2.  Mitogen-activated protein kinases: specific messages from ubiquitous messengers.

Authors:  H J Schaeffer; M J Weber
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.

Authors:  Jacques Dumas; Holia Hatoum-Mokdad; Robert N Sibley; Roger A Smith; William J Scott; Uday Khire; Wendy Lee; Jill Wood; Donald Wolanin; Jeffrey Cooley; Donald Bankston; Aniko M Redman; Robert Schoenleber; Yolanda Caringal; David Gunn; Romulo Romero; Martin Osterhout; Holger Paulsen; Timothy J Housley; Scott M Wilhelm; John Pirro; Du-Shieng Chien; Gerald E Ranges; Alka Shrikhande; Andrew Muzsi; Elizabeth Bortolon; Jean Wakefield; Cynthia Gianpaolo Ostravage; Ajay Bhargava; Thuy Chau
Journal:  Bioorg Med Chem Lett       Date:  2002-06-17       Impact factor: 2.823

Review 4.  MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.

Authors:  Matthew R Lee; Celia Dominguez
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

5.  1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.

Authors:  J Dumas; H Hatoum-Mokdad; R Sibley; B Riedl; W J Scott; M K Monahan; T B Lowinger; C Brennan; R Natero; T Turner; J S Johnson; R Schoenleber; A Bhargava; S M Wilhelm; T J Housley; G E Ranges; A Shrikhande
Journal:  Bioorg Med Chem Lett       Date:  2000-09-18       Impact factor: 2.823

6.  Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.

Authors:  John E Stelmach; Luping Liu; Sangita B Patel; James V Pivnichny; Giovanna Scapin; Suresh Singh; Cornelis E C A Hop; Zhen Wang; John R Strauss; Patricia M Cameron; Elizabeth A Nichols; Stephen J O'Keefe; Edward A O'Neill; Dennis M Schmatz; Cheryl D Schwartz; Chris M Thompson; Dennis M Zaller; James B Doherty
Journal:  Bioorg Med Chem Lett       Date:  2003-01-20       Impact factor: 2.823

7.  The primary structure of p38 gamma: a new member of p38 group of MAP kinases.

Authors:  Z Li; Y Jiang; R J Ulevitch; J Han
Journal:  Biochem Biophys Res Commun       Date:  1996-11-12       Impact factor: 3.575

8.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

9.  Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.

Authors:  Stefan A Laufer; Gerd K Wagner; Dunja A Kotschenreuther; W Albrecht
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  5 in total

1.  FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking protocols.

Authors:  Mohammed H Bohari; G Narahari Sastry
Journal:  J Mol Model       Date:  2012-05-08       Impact factor: 1.810

2.  Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors.

Authors:  Preethi Badrinarayan; P Srivani; G Narahari Sastry
Journal:  J Mol Model       Date:  2010-06-23       Impact factor: 1.810

Review 3.  Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery.

Authors:  Valère Lounnas; Tina Ritschel; Jan Kelder; Ross McGuire; Robert P Bywater; Nicolas Foloppe
Journal:  Comput Struct Biotechnol J       Date:  2013-04-02       Impact factor: 7.271

4.  Lead generation and optimization based on protein-ligand complementarity.

Authors:  Koji Ogata; Tetsu Isomura; Shinji Kawata; Hiroshi Yamashita; Hideo Kubodera; Shoshana J Wodak
Journal:  Molecules       Date:  2010-06-17       Impact factor: 4.411

Review 5.  Pyrazolyl-Ureas as Interesting Scaffold in Medicinal Chemistry.

Authors:  Chiara Brullo; Federica Rapetti; Olga Bruno
Journal:  Molecules       Date:  2020-07-29       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.